Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd
301130
Company Profile
Business description
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co Ltd is mainly engaged in the research, development, production, and sales of chemical APIs and preparations. It is focused on the development and manufacturing of iron supplement preparations, circulatory disorder treatment drugs, anti-psychotic drugs, and APIs. The company's product portfolio comprises Compound Ferrous Sulfate Folic Acid Tablets, Risperidone Orally Disintegrating Tablets, Escitalopram Oxalate Tablets, Daphne Capsules, Zoledronic Acid for Injection, etc., and various APIs.
Contact
No. 777, Xidian Street
Panshi Economic Development Zone
Jilin Province
Panshi132300
CHNT: +86 43265888277
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
320
Stocks News & Analysis
stocks
Wildly overvalued ASX stock is skating on thin ice
This company dominates its industry and could be flirting with regulatory intervention.
stocks
Uber flexes its network effect and delivers strong result
Uber’s business is humming along but autonomous vehicles add uncertainty to the longer term outlook.
stocks
Ask the analyst: Are Qantas shares a value trap?
Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,095.80 | 6.20 | -0.07% |
| CAC 40 | 7,709.32 | 74.29 | 0.97% |
| DAX 40 | 24,192.50 | 268.14 | 1.12% |
| Dow JONES (US) | 43,968.64 | 224.48 | -0.51% |
| FTSE 100 | 9,100.77 | 63.54 | -0.69% |
| HKSE | 25,081.63 | 171.00 | 0.69% |
| NASDAQ | 21,242.70 | 73.27 | 0.35% |
| Nikkei 225 | 41,790.37 | 731.22 | 1.78% |
| NZX 50 Index | 12,903.41 | 16.31 | 0.13% |
| S&P 500 | 6,340.00 | 5.06 | -0.08% |
| S&P/ASX 200 | 8,827.80 | 3.60 | -0.04% |
| SSE Composite Index | 3,639.67 | 5.67 | 0.16% |